Company profile for TScan Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

TScan discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors, and other serious diseases. Our proprietary, high-throughput platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of highly efficacious TCR-Ts with minimal off-target effects. Lead program TSC-100 is expected to enter clin...
TScan discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors, and other serious diseases. Our proprietary, high-throughput platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of highly efficacious TCR-Ts with minimal off-target effects. Lead program TSC-100 is expected to enter clinical development for liquid cancers in 2021, and the Company is advancing additional TCR-Ts for solid cancers.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
830 Winter St. Waltham, Ma 02451
Telephone
Telephone
857-399-9500
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Clinical Outsourcing

Clinical Outsourcing

Not Confirmed

envelop Contact Supplier

Clinical Outsourcing

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2026/02/26/3245412/0/en/TScan-Therapeutics-Completes-Enrollment-in-Cohort-C-of-Phase-1-ALLOHA-Trial-and-Announces-FDA-Clearance-of-Investigational-New-Drug-Applications-for-Heme-Candidates-TSC-102-A01-and.html

GLOBENEWSWIRE
26 Feb 2026

https://www.globenewswire.com/news-release/2026/02/25/3244454/0/en/TScan-Therapeutics-to-Participate-in-the-TD-Cowen-46th-Annual-Health-Care-Conference.html

GLOBENEWSWIRE
25 Feb 2026

https://www.globenewswire.com/news-release/2025/12/06/3201100/0/en/TScan-Therapeutics-Announces-Positive-Updated-Data-from-the-ALLOHA-Phase-1-Heme-Trial-at-the-67th-American-Society-of-Hematology-Annual-Meeting-and-Exposition.html

GLOBENEWSWIRE
06 Dec 2025

https://www.globenewswire.com/news-release/2025/12/03/3199335/0/en/TScan-Therapeutics-to-Host-Virtual-KOL-Event-to-Discuss-Clinical-Updates-from-the-ALLOHA-Phase-1-Trial-and-Future-Market-Opportunities.html

GLOBENEWSWIRE
03 Dec 2025

https://www.globenewswire.com/news-release/2025/11/12/3186072/0/en/TScan-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html

GLOBENEWSWIRE
13 Nov 2025

https://www.globenewswire.com/news-release/2025/11/05/3181271/0/en/TScan-Therapeutics-to-Participate-in-the-Guggenheim-2nd-Annual-Healthcare-Innovation-Conference.html

GLOBENEWSWIRE
05 Nov 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty